Literature DB >> 21924127

[Ulcerative colitis: exceptional consequence after rituximab therapy].

Y Sekkach1, S Hammi, M Elqatni, J Fatihi, M Badaoui, N Elomri, F Mekouar, J Smaali, M Jira, T Amezyane, A Abouzahir, D Ghafir.   

Abstract

INTRODUCTION: Possible adverse complications related to rituximab (RTX) are low, some of which are extremely rare. The authors describe one situation visibly waning exceptional treatment with RTX for SLE refractory to conventional therapies. COMMENT: The authors report a patient of 34 years followed for months for an illness in its bullous lupus, with cutaneous, articular, hematologic and immunologic. Given a corticosteroid resistance, several therapeutic background based hydroxychloroquine, cyclophosphamide and methotrexate, were initiated without any improvement. Immunomodulatory therapy type RTX was introduced to this form refractory at a rate of 375mg/m(2)/week. The waning of the second infusion, the patient presented a sudden intense abdominal pain syndrome, revealing an acute catarrhal appendicitis. At distance from the appendectomy, the consequences of which were favorable, treatment with RTX was resumed. In the aftermath of the third infusion, the patient presented in table tract marked by profuse watery diarrhea whose explorations reveal a morphological endoscopic appearance of erythematous, ulcerative colitis, reversible upon discontinuation of treatment. Histological data revealed important infiltrates composed mainly of CD8T lymphocytes.
CONCLUSION: Gastrointestinal immunological consequences to the requirements of the targeted therapies deserved very careful and rigorous monitoring. However, at the slightest sign of digestive, a detailed morphological exploration is essential, to avoid in particular surgical emergency, evolution without treatment could engage in short-term vital prognosis. 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21924127     DOI: 10.1016/j.pharma.2011.06.005

Source DB:  PubMed          Journal:  Ann Pharm Fr        ISSN: 0003-4509


  3 in total

1.  Fulminant Colitis Following Rituximab Therapy.

Authors:  Seth Lipka; Seymour Katz; James M Crawford
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-01

2.  T regulatory cells and B cells cooperate to form a regulatory loop that maintains gut homeostasis and suppresses dextran sulfate sodium-induced colitis.

Authors:  L Wang; A Ray; X Jiang; J-y Wang; S Basu; X Liu; T Qian; R He; B N Dittel; Y Chu
Journal:  Mucosal Immunol       Date:  2015-03-25       Impact factor: 7.313

Review 3.  Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.

Authors:  Weixun Zhou; Yan Huang; Jinping Lai; Jun Lu; Michael Feely; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2018-05-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.